Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pharmacokinetics of Enzalutamide Clear all
Recruiting Phase 3 Interventional

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

NCT07028853
View directory record Official record
Conditions
Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Interventions
Mevrometostat, Placebo, Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
122
States / cities
Huntsville, Alabama • Chandler, Arizona • Gilbert, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 23, 2026, 1:22 AM EDT
Completed Phase 1 Interventional Results available

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

NCT01597193
View directory record Official record
Conditions
Breast Cancer
Interventions
enzalutamide, anastrozole, exemestane, fulvestrant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
17
States / cities
Aurora, Colorado • Enfield, Connecticut • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Jul 23, 2026, 1:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02711956
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
ZEN003694, Enzalutamide
Drug
Lead sponsor
Zenith Epigenetics
Industry
Eligibility
18 Years and older · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Jul 23, 2026, 1:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 (Alobresib) as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

NCT02607228
View directory record Official record
Conditions
Metastatic Castrate-Resistant Prostate Cancer
Interventions
Alobresib, Enzalutamide
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
San Francisco, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Jul 23, 2026, 1:22 AM EDT
Completed Phase 1 Interventional

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

NCT02740985
View directory record Official record
Conditions
Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
Interventions
AZD4635, Durvalumab, Abiraterone Acetate, Enzalutamide, Oleclumab, Docetaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
17
States / cities
Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Jul 23, 2026, 1:22 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

NCT06629779
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
PF-06821497, Placebo, Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
44
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 23, 2026, 1:22 AM EDT
Completed Phase 1 Interventional

Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients

NCT01902251
View directory record Official record
Conditions
Prostate Cancer, Pharmacokinetics of Enzalutamide
Interventions
Enzalutamide tablet, Enzalutamide capsule
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Denver, Colorado • Chicago, Illinois • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Jul 23, 2026, 1:22 AM EDT
Completed Phase 1 Interventional Results available

Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)

NCT04179396
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
Rucaparib, Enzalutamide, Abiraterone
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Atlanta, Georgia • Minneapolis, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Jul 23, 2026, 1:22 AM EDT
Completed Phase 1 Interventional

Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients

NCT03569280
View directory record Official record
Conditions
Castration-Resistant Prostate Cancer
Interventions
Enzalutamide or Abiraterone or Apalutamid
Combination Product
Lead sponsor
Kangpu Biopharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Las Vegas, Nevada • Port Jefferson Station, New York • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Jul 23, 2026, 1:22 AM EDT
Recruiting Phase 1 Interventional

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

NCT07277270
View directory record Official record
Conditions
Neoplasms
Interventions
GSK5764227, Bevacizumab, Fluorouracil, leucovorin, Enzalutamide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 23, 2026, 1:22 AM EDT
Active, not recruiting Phase 2 Interventional

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

NCT04557449
View directory record Official record
Conditions
Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung
Interventions
PF-07220060, Letrozole, Fulvestrant, Midazolam, Enzalutamide
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
11
States / cities
Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jul 23, 2026, 1:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT03437941
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer
Interventions
Exicorilant, Enzalutamide, Placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
6
States / cities
Scottsdale, Arizona • Detroit, Michigan • Basking Ridge, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 23, 2026, 1:22 AM EDT
Terminated Phase 1 Interventional Results available

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

NCT03150056
View directory record Official record
Conditions
Solid Tumours
Interventions
GSK525762, Abiraterone, Enzalutamide, Prednisone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Male only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
9
States / cities
Los Angeles, California • Baltimore, Maryland • Towson, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Jul 23, 2026, 1:22 AM EDT
Completed Phase 1 Interventional

A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer

NCT02991911
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
MEDI3726 Post-Chemo, MEDI3726 Pre-Chemo, MEDI3726 & Enzalutamide Combo
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
New Haven, Connecticut • Sarasota, Florida • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jul 23, 2026, 1:22 AM EDT